Delta 9 Cannabis: Picking a Path to Growth during Turbulent Times Custom Case Solution & Analysis

Evidence Brief: Delta 9 Cannabis

1. Financial Metrics

Revenue Growth: Reported revenue increased from 0.6 million dollars in 2017 to 31.8 million dollars in 2019.
Profitability: Achieved positive adjusted EBITDA of 2.1 million dollars in 2019, distinguishing the firm from many Canadian peers reporting significant losses.
Capital Position: Cash and cash equivalents stood at 13.5 million dollars as of year end 2019.
Market Valuation: Stock price peaked near 2.80 dollars in early 2018 before declining below 0.50 dollars by mid 2020, reflecting broader sector contraction.
Revenue Mix: Retail sales accounted for approximately 65 percent of total revenue in 2019, while wholesale and B2B pod sales contributed the remainder.

2. Operational Facts

Production Method: Utilizes proprietary modular Grow Pod technology — repurposed shipping containers — allowing for vertical integration and isolation of crops to prevent mass contamination.
Capacity: Production facility in Winnipeg, Manitoba, reached a capacity of approximately 8,300 kilograms per year by 2020.
Retail Footprint: Operated 4 retail stores in Manitoba by late 2019 with plans to expand to 20 stores across Western Canada.
B2B Segment: Sold over 200 Grow Pods to other licensed producers, providing a high margin revenue stream without the biological risk of cultivation.
Geography: Primary operations and headquarters located in Winnipeg, Manitoba, with retail expansion targets in Saskatchewan and Alberta.

3. Stakeholder Positions

Arbuthnot Family: Founders Niles and John Arbuthnot maintain significant equity and leadership roles, prioritizing long term sustainability over aggressive, loss making growth.
Licensed Producers (LPs): Competitors face massive inventory write downs and facility closures due to oversupply in the Canadian market.
Health Canada: The regulatory body maintains strict licensing requirements for both production facilities and retail locations, creating significant lead times.
Investors: Shifted focus from top line revenue growth to path to profitability and cash flow preservation.

4. Information Gaps

Consumer Loyalty: Lack of data on brand switching costs versus price sensitivity in the retail segment.
International Regulatory Timelines: Uncertainty regarding when European or American markets will allow import of Canadian produced cannabis or Grow Pod technology.
Competitor Cost Structures: Detailed unit economics of large scale greenhouse producers compared to Delta 9 modular pod costs are not fully disclosed.

Strategic Analysis

1. Core Strategic Question

How should Delta 9 allocate limited capital across its three business segments — cultivation, retail, and B2B equipment — to sustain profitability while competitors with larger balance sheets face insolvency?

2. Structural Analysis

Vertical Integration Value Chain: Delta 9 controls the entire chain from equipment manufacturing to retail. This structure mitigates the industry wide oversupply crisis. While other producers have excess biomass with no outlet, Delta 9 uses its retail arm to clear its own inventory at higher captured margins. However, the B2B Grow Pod segment operates on a different logic, acting as a technology provider to the very competitors who might struggle to pay.

Porter Five Forces Applied: Rivalry is extreme due to industry oversupply. Buyer power is increasing as consumers demand lower prices per gram. Supplier power for Delta 9 is low because they manufacture their own production units. The threat of substitutes — the illicit market — remains the primary ceiling on retail pricing and remains a persistent 40 to 50 percent of the total market share.

3. Strategic Options

Option 1: Retail Dominance. Aggressively acquire distressed retail assets in Western Canada. Rationale: Retail provides the most stable cash flow and direct access to consumers. Trade-offs: Requires significant upfront capital and increases exposure to regional labor market fluctuations. Resource Requirements: 10 to 15 million dollars in acquisition capital and a dedicated store integration team.

Option 2: B2B Technology Pivot. Shift focus from cultivation to selling Grow Pods and consulting services globally. Rationale: Higher margins and lower biological risk than growing plants. Trade-offs: Revenue is lumpy and dependent on the capital expenditure cycles of other producers. Resource Requirements: International sales force and intellectual property protection legal counsel.

Option 3: Cultivation Scale-Up. Expand the Winnipeg facility to maximize economies of scale. Rationale: Lowering the cost per gram to compete with large scale greenhouse producers. Trade-offs: Highest risk of inventory obsolescence and price compression. Resource Requirements: Significant facility expansion permits and increased electricity/utility commitments.

4. Preliminary Recommendation

Delta 9 must prioritize Option 1 (Retail) and use Option 2 (B2B) as a secondary cash generator. Cultivation expansion should be paused. The Canadian market is currently oversupplied; adding more capacity is a poor use of capital. Retail stores provide a captive channel for Delta 9 products, ensuring the production facility stays at 100 percent utilization while capturing the full retail markup. This defensive integration is the only viable path to surviving the current sector downturn.

Implementation Roadmap

1. Critical Path

Month 1-3: Identify 5 to 8 distressed retail locations in Alberta and Saskatchewan for acquisition. Finalize standardized store operating procedures to ensure rapid integration.
Month 4-6: Close acquisitions and rebrand stores to Delta 9. Redirect 40 percent of internal production to these new channels.
Month 7-12: Launch a B2B marketing campaign targeting US and European markets for Grow Pod sales, contingent on local legal shifts.

2. Key Constraints

Regulatory Lag: Health Canada and provincial boards often take 6 to 9 months to approve license transfers. This delay can drain cash reserves before a store becomes operational.
Capital Availability: With the stock price depressed, equity financing is dilutive. Expansion must be funded primarily through operational cash flow and limited debt.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of regulatory delays, Delta 9 should utilize a phased acquisition model where payments are tied to the successful transfer of licenses. The company must maintain a minimum cash buffer of 5 million dollars to survive potential market shutdowns or unexpected price wars. If retail margins compress by more than 15 percent, the company must pivot to a pure B2B equipment model to preserve the balance sheet.

Executive Review and BLUF

1. BLUF

Delta 9 should freeze all cultivation expansion and pivot exclusively to a retail-first strategy supported by B2B equipment sales. The Canadian cannabis market suffers from structural oversupply. Owning the shelf is the only way to guarantee product movement and protect margins. The company must utilize its 13.5 million dollar cash position to acquire distressed retail assets in Western Canada while competitors are unable to access capital. This strategy secures a distribution moat and ensures the Winnipeg production facility remains a profit center rather than a cost burden. Speed in retail acquisition is now the primary determinant of survival.

2. Dangerous Assumption

The analysis assumes that retail margins will remain stable. In reality, provincial wholesalers control the pricing, and a sudden downward shift in government mandated margins could render the retail expansion strategy unprofitable overnight.

3. Unaddressed Risks

Inventory Obsolescence: If consumer preferences shift toward specific strains or product formats like edibles faster than the modular pods can be recalibrated, Delta 9 will be left with unsellable biomass.
Liquidity Crunch: The plan relies on operational cash flow to fund growth. A 20 percent drop in market prices would halt expansion and threaten debt covenants.

4. Unconsidered Alternative

The team did not evaluate a complete exit from cultivation. Selling the Winnipeg facility and becoming a pure play retailer and equipment provider would eliminate biological risk and significantly reduce utility and labor costs, potentially yielding a higher return on equity.